<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462043</url>
  </required_header>
  <id_info>
    <org_study_id>ND0612-315</org_study_id>
    <nct_id>NCT03462043</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension</brief_title>
  <official_title>A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the relative bioavailability of s.c. infused ND0612 versus jejunally
      infused CLES in patients with advanced PD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label, randomized, crossover study to assess the relative
      bioavailability of s.c. infused ND0612 versus jejunally infused CLES in patients with
      advanced PD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>6-7 days</time_frame>
    <description>To assess relative bioavailability of levodopa (LD) administered as ND0612, infused subcutaneously (s.c.), versus LD administered as carbidopa-levodopa enteral suspension (CLES)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ND0612</intervention_name>
    <description>s.c. infused</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CLES</intervention_name>
    <description>Carbidopa-Levodopa Enteral Suspension.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Advanced PD treated with LD/CD at a dose of at least 800 mg LD

          -  Female patients must have a negative pregnancy test at screening and at admission.

          -  Patients must have a body mass index (BMI) within the range of 18.5 - 35 kg/m2, where
             BMI = body weight (kg) / height (m2) at screening.

          -  Must be willing and able to communicate and participate in the whole study.

          -  Must provide written informed consent.

          -  Must agree to use an adequate method of contraception (per local independent ethics
             committee requirements).

          -  Area of administration to be evaluable for local skin reaction (normal skin without
             skin burns, scars or large tattoos in the area of administration

        Exclusion Criteria:

          -  Any relevant medical, surgical, or psychiatric condition, laboratory value, or
             concomitant medication which, in the opinion of the Investigator, makes the patient
             unsuitable for study entry or potentially unable to complete all aspects of the study.

          -  Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human
             Immunodeficiency Virus (HIV) at the screening visit.

          -  Patients with a history of drug abuse or alcoholism within the past 12 months prior to
             screening or positive drugs of abuse or alcohol test result at the screening visit
             and/or on admission.

          -  Clinically significant electrocardiogram (ECG) rhythm abnormalities.

          -  Renal or liver dysfunction that may alter drug metabolism including: serum creatinine
             &gt;1.5 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
             &gt;2 x upper limit of normal (ULN), total serum bilirubin &gt;2.5 mg/dL.

          -  Psychiatric, neurological or behavioral disorders that may interfere with the conduct
             or interpretation of the study, including dementia, or patients who are considered to
             be violent or at suicidal risk by the Investigator.

          -  Blood loss of greater than 500 mL within the previous 3 months prior to first dosing.

          -  use of any medication from the prohibited concomitant therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osnat Ehrman</last_name>
    <role>Study Director</role>
    <affiliation>NeuroDerm Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osnat Ehrman, MSc</last_name>
    <phone>+972-8-9462729</phone>
    <email>info@neuroderm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>91601</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>91601</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

